Sequential CD7 CAR T-Cell Therapy and Allogeneic HSCT without GVHD Prophylaxis.
Yongxian HuMingming ZhangTingting YangZhuomao MoGuoqing WeiRuirui JingHouli ZhaoRongrong ChenCheng ZuTianning GuPingnan XiaoRuimin HongJingjing FengShan FuDelin KongHuijun XuJiazhen CuiSimao HuangBin LiangXiaolin YuanQu CuiHongshan GuoYunxian YuYouqin FengChunxiang JinJiangtao RenAlex H ChangDongrui WangHe HuangPublished in: The New England journal of medicine (2024)
Our findings suggest that sequential CD7 CAR T-cell therapy and haploidentical HSCT is safe and effective, with remission and serious but reversible adverse events. This strategy offers a feasible approach for patients with CD7-positive tumors who are ineligible for conventional allogeneic HSCT. (Funded by the National Natural Science Foundation of China and the Key Project of Science and Technology Department of Zhejiang Province; ClinicalTrials.gov numbers, NCT04599556 and NCT04538599.).